I’ve just finished this interesting book on the biography of cancer.
On one hand, it’s a depressing story, as we are still losing too many battles.
On the other hand, there are many ways that progress have been made and hopefully, we are in a phase (e.g. genomics research and the cost reduction in analyzing DNA) that will bring us more victories.
It is a story about the history of research with eureka moments and decades of despair.
The author, Dr Mukherjee does a great job in describing the history from its first documented appearances thousands of years ago (when the Greek historian Herodotus records the story of Atossa the queen of Persia and the daughter of Cyrus, who noticed a lump in her breast.) through the progress in the twentieth century to cure, control, and conquer it to a radical new understanding of its essence.
I found somewhere this encouraging answer he gave to the question “With all that you have learned up to this point, are you hopeful in terms of cancer research and possible cures?”
Mukherjee: “I feel pathologically hopeful!
The opposite of hopeful is hopeless.
How can you be hopeless?
Discoveries have occurred, and discoveries are occurring.
Look at history, does that mean that every move becomes the most brilliant discovery or the universal cure for cancer?
No.
But history clearly shows a track record of progress. Medicine is caught in this moment of pulling out from a sea of uncertainty these little pieces that are more certain than others. I often tell fellows and residents, to me there is no discipline we practice as human beings that manage this level of complexity. Not just statistical or scientific complexity, but emotional complexity. That’s what makes it one of the most unbelievably moving professions that exist.”
How can move encourage more brilliant minds to go and invest in this important research instead of how to ‘waste’ more people time on Ads or ‘what their friends are doing’?
How can we see more startups that focus on new treatments and drugs (that won’t cost $2B to develop)?
Maybe, change the way the FDA is forcing the drug companies to test its products?
I hope we will see some significant improvements in this domain during our lifetime.
[Update 9/8/2019] — I’ve just saw this set of startups that got funding to keep the research going and get us more ‘wins’:
- Nkarta Therapeutics collected $114 million in Series B funding to further develop its “natural killer cell therapies.”
- Achilles Therapeutics banked £100 million (about $123 million) for its personalized cancer therapies.
- Repare Therapeutics hauled in $82.5 million to finance its precision oncology efforts.”
Originally published at greenido.wordpress.com on December 10, 2018.
